Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects
Status:
Unknown status
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to treat prospectively documented clinic patients with
treatment-refractory multiple sclerosis that are naïve to alemtuzumab. Alemtuzumab shows
efficacy and rate of serious adverse events (SAEs) which is equivalent or better than
standard of care treatment strategies used previously for treatment-refractory multiple
sclerosis.